This week: The government makes a $1.95 billion deal for a COVID-19 vaccine; Promising data from the Oxford vaccine trial; The CDC retakes control of COVID-19 data; Novel calcineurin inhibitor for lupus nephritis gets priority review; And there’s new treatment for narcolepsy.
To expedite development, the FDA has created a special emergency program called the Coronavirus Treatment Acceleration Program.
Professional societies issue stern warning not to inappropriately prescribe meds for COVID-19.
Researchers addressed the association between cardiovascular risk and glucocorticoids in patients with systemic lupus erythematosus.
Researchers compared the rate of opioid overdose-related hospitalizations among patients with systemic lupus erythematosus and rheumatoid arthritis vs the general population.
Researchers examined the association of blood levels of hydroxychloroquine with thrombotic events in a longitudinal systemic lupus erythematous cohort.
